Last reviewed · How we verify
EVM14
At a glance
| Generic name | EVM14 |
|---|---|
| Sponsor | Everest Medicines (Beijing) Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EVM14 CI brief — competitive landscape report
- EVM14 updates RSS · CI watch RSS
- Everest Medicines (Beijing) Co., Ltd. portfolio CI